Expert Opinion on Therapeutic Patents最新文献_第9页

Proteasome inhibitors as anticancer agents. 蛋白酶体抑制剂作为抗癌剂。

IF 6.6 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2023-11-01 Epub Date: 2024-01-11 DOI: 10.1080/13543776.2023.2272648

Giorgia Gazzaroli, Andrea Angeli, Arianna Giacomini, Roberto Ronca

{"title":"Proteasome inhibitors as anticancer agents.","authors":"Giorgia Gazzaroli, Andrea Angeli, Arianna Giacomini, Roberto Ronca","doi":"10.1080/13543776.2023.2272648","DOIUrl":"10.1080/13543776.2023.2272648","url":null,"abstract":"Introduction: The therapeutic targeting of the ubiquitin-proteasome pathway (UPP) through inhibitors of the 20S proteasome core proteolytic activities has revolutionized the treatment of hematological malignancies and is paving the way for its extension to solid tumors.Areas covered: This review covers the progress made in the field of proteasome inhibitors, ranging from the first-generation bortezomib to the latest second-generation inhibitors such as carfilzomib and ixazomib as well as the proteasome inhibitors in clinical phase such as oprozomib and marizomib. The development of selective and potent proteasome inhibitors with improved pharmacological properties is described from the synthesis to their basic biological, and clinical validation.Expert opinion: Proteasome inhibitors have transformed the treatment landscape for hematological malignancies and hold great promise for cancer therapy. Combination therapies targeting multiple pathways, the development of novel inhibitors or 'hybrid-inhibitors,' and the optimization of treatment protocols are key areas for future exploration. The extension of proteasome inhibitors for the treatment of solid tumors, and their ability to pass the blood-brain barrier open new possibilities for treating central nervous system cancers. However, managing adverse effects, particularly those affecting the central nervous system, remains a critical consideration and a strategic 'working on' aspect for the near future.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"775-796"},"PeriodicalIF":6.6,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41233757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

G-quadruplexes in cancer-related gene promoters: from identification to therapeutic targeting. 癌症相关基因启动子中的G-quadruplex：从鉴定到治疗靶向。

IF 6.6 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2023-11-01 Epub Date: 2024-01-11 DOI: 10.1080/13543776.2023.2271168

Francesca Romano, Anna Di Porzio, Nunzia Iaccarino, Gelsomina Riccardi, Ritamaria Di Lorenzo, Sonia Laneri, Bruno Pagano, Jussara Amato, Antonio Randazzo

{"title":"G-quadruplexes in cancer-related gene promoters: from identification to therapeutic targeting.","authors":"Francesca Romano, Anna Di Porzio, Nunzia Iaccarino, Gelsomina Riccardi, Ritamaria Di Lorenzo, Sonia Laneri, Bruno Pagano, Jussara Amato, Antonio Randazzo","doi":"10.1080/13543776.2023.2271168","DOIUrl":"10.1080/13543776.2023.2271168","url":null,"abstract":"Introduction: Guanine-rich DNA sequences can fold into four-stranded noncanonical secondary structures called G-quadruplexes (G4s) which are widely distributed in functional regions of the human genome, such as telomeres and gene promoter regions. Compelling evidence suggests their involvement in key genome functions such as gene expression and genome stability. Notably, the abundance of G4-forming sequences near transcription start sites suggests their potential involvement in regulating oncogenes.Areas covered: This review provides an overview of current knowledge on G4s in human oncogene promoters. The most representative G4-binding ligands have also been documented. The objective of this work is to present a comprehensive overview of the most promising targets for the development of novel and highly specific anticancer drugs capable of selectively impacting the expression of individual or a limited number of genes.Expert opinion: Modulation of G4 formation by specific ligands has been proposed as a powerful new tool to treat cancer through the control of oncogene expression. Actually, most of G4-binding small molecules seem to simultaneously target a range of gene promoter G4s, potentially influencing several critical driver genes in cancer, thus producing significant therapeutic benefits.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"745-773"},"PeriodicalIF":6.6,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49676121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development of tubulin polymerization inhibitors as anticancer agents. 开发作为抗癌剂的微管蛋白聚合抑制剂。

IF 6.6 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2023-11-01 Epub Date: 2024-01-11 DOI: 10.1080/13543776.2023.2291390

Mudasir Nabi Peerzada, Mohammad Sultan Dar, Saurabh Verma

{"title":"Development of tubulin polymerization inhibitors as anticancer agents.","authors":"Mudasir Nabi Peerzada, Mohammad Sultan Dar, Saurabh Verma","doi":"10.1080/13543776.2023.2291390","DOIUrl":"10.1080/13543776.2023.2291390","url":null,"abstract":"Introduction: Microtubules are intracellular, filamentous, polymeric structures that extend throughout the cytoplasm, composed of α-tubulin and β-tubulin subunits. They regulate many cellular functions including cell polarity, cell shape, mitosis, intracellular transport, cell signaling, gene expression, cell integrity, and are associated with tumorigenesis. Inhibition of tubulin polymerization within tumor cells represents a crucial focus in the pursuit of developing anticancer treatments.Areas covered: This review focuses on the natural product and their synthetic congeners as tubulin inhibitors along with their site of interaction on tubulin. This review also covers the developed novel tubulin inhibitors and important patents focusing on the development of tubulin inhibition for cancer treatment reported from 2018 to 2023. The scientific and patent literature has been searched on PubMed, Espacenet, ScienceDirect, and Patent Guru from 2018-2023.Expert opinion: Tubulin is one of the promising targets explored extensively for drug discovery. Compounds binding in the colchicine site could be given importance because they can elude resistance mediated by the P-glycoprotein efflux pump and no colchicine site binding inhibitor is approved by FDA so far. The research on the development of antibody drug conjugates (ADCs) for tubluin polymerization inhibition could be significant strategy for cancer treatment.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"797-820"},"PeriodicalIF":6.6,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138487058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A patent review on aldehyde dehydrogenase inhibitors: an overview of small molecule inhibitors from the last decade. 醛脱氢酶抑制剂专利综述:近十年来小分子抑制剂的研究概况。

IF 6.6 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2023-10-01 Epub Date: 2024-01-10 DOI: 10.1080/13543776.2023.2287515

Biswajit Kundu, Malliga R Iyer

{"title":"A patent review on aldehyde dehydrogenase inhibitors: an overview of small molecule inhibitors from the last decade.","authors":"Biswajit Kundu, Malliga R Iyer","doi":"10.1080/13543776.2023.2287515","DOIUrl":"10.1080/13543776.2023.2287515","url":null,"abstract":"Introduction: Physiological and pathophysiological effects arising from detoxification of aldehydes in humans implicate the enzyme aldehyde dehydrogenase (ALDH) gene family comprising of 19 isoforms. The main function of this enzyme family is to metabolize reactive aldehydes to carboxylic acids. Dysregulation of ALDH activity has been associated with various diseases. Extensive research has since gone into studying ALHD isozymes, their structural biology and developing small-molecule inhibitors. Novel chemical strategies to enhance the selectivity of ALDH inhibitors have now appeared.Areas covered: A comprehensive review of patent literature related to aldehyde dehydrogenase inhibitors in the last decade and half (2007-2022) is provided.Expert opinion: Aldehyde dehydrogenase (ALDH) is an important enzyme that metabolizes reactive exogenous and endogenous aldehydes in the body through NAD(P)±dependent oxidation. Hence this family of enzymes possess important physiological as well as toxicological roles in human body. Significant efforts in the field have led to potent inhibitors with approved clinical agents for alcohol use disorder therapy. Further clinical translation of novel compounds targeting ALDH inhibition will validate the promised therapeutic potential in treating many human diseases.The scientific/patent literature has been searched on SciFinder-n, Reaxys, PubMed, Espacenet and Google Patents. The search terms used were 'ALDH inhibitors', 'Aldehyde Dehydrogenase Inhibitors'.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"651-668"},"PeriodicalIF":6.6,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138458941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

SREBP inhibitors: an updated patent review for 2008-present. SREBP 抑制剂：2008 年至今的最新专利回顾。

IF 6.6 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2023-10-01 Epub Date: 2024-01-10 DOI: 10.1080/13543776.2023.2291393

Zhenyu Peng, Leyuan Chen, Manjiang Wang, Xufan Yue, Huiqiang Wei, Feifei Xu, Wenbin Hou, Yiliang Li

{"title":"SREBP inhibitors: an updated patent review for 2008-present.","authors":"Zhenyu Peng, Leyuan Chen, Manjiang Wang, Xufan Yue, Huiqiang Wei, Feifei Xu, Wenbin Hou, Yiliang Li","doi":"10.1080/13543776.2023.2291393","DOIUrl":"10.1080/13543776.2023.2291393","url":null,"abstract":"Introduction: Sterol regulatory element-binding proteins (SREBPs) are a family of membrane-binding transcription factors that activate genes encoding enzymes required for cholesterol and unsaturated fatty acid synthesis. Overactivation of SREBP is related to the occurrence and development of diabetes, nonalcoholic fatty liver, tumor, and other diseases. In the past period, many SREBP inhibitors have been found.Areas covered: This manuscript is a patent review of SREBP inhibitors. We searched 2008 to date for all data from the US patent database (https://www.uspto.gov/) and the European patent database (https://www.epo.org/) with 'SREBP' and 'inhibitor' as keywords and analyzed the search results.Expert opinion: Both synthetic and natural SREBP inhibitors have been reported. Despite the lack of cocrystal structure of SREBP inhibitor, the mechanisms of several compounds have been clarified. Importantly, some SREBP inhibitors have been proved to have good activity in preclinical studies. As the characteristics of lipid metabolism reprogramming in cardio-cerebrovascular diseases and tumors are gradually revealed, more and more attention will be focused on SREBP.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"669-680"},"PeriodicalIF":6.6,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138487059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An updated patent review of matrix metalloproteinase (MMP) inhibitors (2021-present). 基质金属蛋白酶(MMP)抑制剂专利综述(2021年至今)

IF 6.6 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2023-10-01 Epub Date: 2024-01-10 DOI: 10.1080/13543776.2023.2284935

Suvankar Banerjee, Sandip Kumar Baidya, Nilanjan Adhikari, Tarun Jha

{"title":"An updated patent review of matrix metalloproteinase (MMP) inhibitors (2021-present).","authors":"Suvankar Banerjee, Sandip Kumar Baidya, Nilanjan Adhikari, Tarun Jha","doi":"10.1080/13543776.2023.2284935","DOIUrl":"10.1080/13543776.2023.2284935","url":null,"abstract":"Introduction: Matrix metalloproteinases (MMPs) are strongly interlinked with the progression and mechanisms of several life-threatening diseases including cancer. Thus, novel MMP inhibitors (MMPIs) as promising drug candidates can be effective in combating these diseases. However, no MMPIs are marketed to date due to poor pharmacokinetics and lower selectivity. Therefore, this review was performed to study the newer MMPIs patented after the COVID-19 period for an updated perspective on MMPIs.Areas covered: This review highlights patents related to MMPIs, and their therapeutic implications published between January 2021 and August 2023 available in the Google Patents, Patentscope, and Espacenet databases.Expert opinion: Despite various MMP-related patents disclosed up to 2020, newer patent applications in the post-COVID-19 period decreased a lot. Besides major MMPs, other isoforms (i.e. MMP-3 and MMP-7) have gained attention recently for drug development. This may open up newer dimensions targeting these MMPs for therapeutic advancements. The isoform selectivity and bioavailability are major concerns for effective MMPI development. Thus, adopting theoretical approaches and experimental methodologies can unveil the development of novel MMPIs with improved pharmacokinetic profiles. Nevertheless, the involvement of MMPs in cancer, and the mechanisms of such MMPs in other diseases should be extensively studied for novel MMPI development.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"631-649"},"PeriodicalIF":6.6,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138046694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nanoparticles in pancreatic cancer therapy: a detailed and elaborated review on patent literature. 纳米颗粒在胰腺癌治疗:专利文献的详细和详细的审查。

IF 6.6 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2023-10-01 Epub Date: 2024-01-10 DOI: 10.1080/13543776.2023.2287520

Mohini Singh, Bani Kumar Jana, Paulami Pal, Ishita Singha, Ananya Rajkumari, Pinky Chowrasia, Venessa Nath, Bhaskar Mazumder

{"title":"Nanoparticles in pancreatic cancer therapy: a detailed and elaborated review on patent literature.","authors":"Mohini Singh, Bani Kumar Jana, Paulami Pal, Ishita Singha, Ananya Rajkumari, Pinky Chowrasia, Venessa Nath, Bhaskar Mazumder","doi":"10.1080/13543776.2023.2287520","DOIUrl":"10.1080/13543776.2023.2287520","url":null,"abstract":"Introduction: Nanotechnology may open up new avenues for overcoming the challenges of pancreatic cancer therapy as a broad arsenal of anticancer medicines fail to realize their full therapeutic potential in pancreatic ductal adenocarcinoma due to the formation of multiple resistance mechanisms inside the tumor. Many studies have reported the successful use of various nano formulations in pancreatic cancer therapy.Areas covered: This review covers all the major nanotechnology-based patent litrature available on renowned patent data bases like Patentscope and Espacenet, through the time period of 2007-2022. This is an entirely patent centric review, and it includes both clinical and non-clinical data available on nanotechnology-based therapeutics and diagnostic tools for pancreatic cancer.Expert opinion: For the sake of understanding, the patents are categorized under various formulation-specific heads like metallic/non-metallic nanoparticles, polymeric nanoparticles, liposomes, carbon nanotubes, protein nanoparticles and liposomes. This distinguishes one specific nanoparticle type from another and makes this review a one-of-a-kind comprehensive patent compilation that has not been reported so far in the history of nanotechnological formulations in pancreatic cancer.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"681-699"},"PeriodicalIF":6.6,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138290697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An updated patent review of AKT inhibitors (2020 - present). Akt抑制剂的最新专利综述（2020年至今）。

IF 6.6 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2023-07-01 Epub Date: 2023-11-28 DOI: 10.1080/13543776.2023.2273895

Linjie Li, Yu Guo, Yang Lu, Yaping Xu, Yan Lu, Xiuping Zhu, Xiaowu Dong, Jinxin Che

{"title":"An updated patent review of AKT inhibitors (2020 - present).","authors":"Linjie Li, Yu Guo, Yang Lu, Yaping Xu, Yan Lu, Xiuping Zhu, Xiaowu Dong, Jinxin Che","doi":"10.1080/13543776.2023.2273895","DOIUrl":"10.1080/13543776.2023.2273895","url":null,"abstract":"Introduction: Protein kinase B (Akt), an essential protein in the PI3K/Akt/mTOR signaling pathway, plays a crucial role in tumor progression. Over the past two years, different types of Akt modulators have continued to emerge in the patent literature.Areas covered: This review focuses on the patent literature covering small molecule inhibitors, peptides, PROTACs, and antisense nucleic acids targetingAkt from 2020 to present. Also, we discuss the outcomes of several clinical trials, combination strategies for different mechanisms, and the application of Akt regulators in other non-oncology indications.Our search for relevant information was conducted using various databases, including the European Patent Office, SciFinder, andPubMed, from 01.2020 to 04.2023.Expert opinion: In recent years, some combination therapeutic strategies involvingAkt inhibitors have shown promising clinical outcomes. Future research can be directed toward developing new applications of Akt inhibitors, which may have implications for other diseases beyond cancer. New attempts suggest that targeting allosteric sites may be a potential solution to the problem of isoform selectivity.Furthermore, directly knocking out Akt protein by using the degraderssuggests a promising direction for future development.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"549-564"},"PeriodicalIF":6.6,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49676120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Type I inhibitors of tropomyosin receptor kinase (Trk): a 2020-2022 patent update. 原肌球蛋白受体激酶（Trk）的I型抑制剂：2020-2022年专利更新。

IF 6.6 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2023-07-01 Epub Date: 2023-11-06 DOI: 10.1080/13543776.2023.2262136

Carolin Jaworski, Petar Iliev, Carmen Wängler, Björn Wängler, Brent Page, Ralf Schirrmacher, Justin J Bailey

{"title":"Type I inhibitors of tropomyosin receptor kinase (Trk): a 2020-2022 patent update.","authors":"Carolin Jaworski, Petar Iliev, Carmen Wängler, Björn Wängler, Brent Page, Ralf Schirrmacher, Justin J Bailey","doi":"10.1080/13543776.2023.2262136","DOIUrl":"10.1080/13543776.2023.2262136","url":null,"abstract":"Introduction: Trk inhibitors are significant in the realm of personalized medicine as they target specific genetic alterations, such as NTRK gene fusions, leading to improved treatment outcomes for cancer patients. By tailoring the treatment to the genetic characteristics of the tumor rather than the tumor type, Trk inhibitors offer the potential for more effective and precise therapies, resulting in enhanced response rates and prolonged survival for patients with NTRK fusion-positive cancers.Areas covered: Patents covering type I inhibitors targeting the Trk family are discussed, building upon our prior review series on Trk inhibitors. Relevant patents were identified through the Web of Science database, Google, and Google Patents.Expert opinion: The field of Trk inhibitors has evolved significantly, as reflected in the current patent literature, which emphasizes the selective structural refinement of clinical champions. Efforts now concentrate on enhancing efficacy against on-target resistance mechanisms, with modifications made to improve potency, reduce toxicity, and enhance pharmacokinetics. Combination therapies show potential to address off-target resistance mechanisms and improve treatment outcomes. Challenges remain in accurately diagnosing NTRK gene alterations and integrating screening into routine clinical practice. Trk inhibitors have surpassed their conventional role of inhibition and are now seeing new applications in radiopharmaceutical development and as molecular targeting agents.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"503-521"},"PeriodicalIF":6.6,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41147051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

N-acetylgalactosamine delivery systems for RNA therapeutics: a patent perspective. 用于RNA治疗的N-乙酰氨基半乳糖递送系统：专利视角。

IF 6.6 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2023-07-01 Epub Date: 2023-11-28 DOI: 10.1080/13543776.2023.2277249

Hai-Long Zhang, Lansuo Wang

{"title":"N-acetylgalactosamine delivery systems for RNA therapeutics: a patent perspective.","authors":"Hai-Long Zhang, Lansuo Wang","doi":"10.1080/13543776.2023.2277249","DOIUrl":"10.1080/13543776.2023.2277249","url":null,"abstract":"Introduction: SiRNA molecules with a feature of good gene-silencing are critical for drug discovery and development based on RNA interference. GalNAc-RNA therapeutics is a rapid growing area in RNA therapeutics.Areas covered: This article provides patent landscape and modification feature of GalNAc-RNA therapeutics. The US-granted patents from January 2004 to April 2023 were retrieved and analyzed.Expert opinion: Globally, our study is the first one to holistically depict a map of modifications and therapeutic applications for GalNAc-RNA therapeutics by patent data analysis. The results showed there were 8 major modifications and 5 new emerged modifications for GalNAc-RNA therapeutic agents. Especially, the study provides recent new emerged modifications in sugar, base, and internucleotide linkage of GalNAc-RNA therapeutic agents, e.g. morpholino-type ring, 5-methylcytosine, and phosphorodithioates. In addition, our study systematically demonstrated major therapeutic applications for GalNAc-RNA therapeutics, including liver or gallbladder disorders, anticancer, antihyperlipidemics, and disorders of the nervous system etc.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"539-547"},"PeriodicalIF":6.6,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61561764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0